IDEAYA Biosciences enters $350M at-the-market stock offering with Jefferies

IDEAYA Biosciences, Inc.

Up to $350M in common stock may be sold from time to time through Jefferies as sales agent.
Jefferies receives 3% commission on gross proceeds; Company sets sale parameters.
Shares issued under existing Form S-3 registration statement; prospectus supplement filed Jan 19, 2024.
ATM program provides at-the-market offering flexibility; no minimum offering amount required.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IDEAYA Biosciences, Inc. entered into Open Market Sales Agreement with Jefferies LLC valued at up to $350,000,000 (effective 2024-01-19).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $350,000,000
Effective: 2024-01-19

Exact text from the filing

On January 19, 2024, IDEAYA Biosciences, Inc. (the “Company”) entered into an Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross proceeds of up to $350.0 million (the “Shares”) through Jefferies as its sales agent.

View on SEC.gov

Browse all material agreements →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-011346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.